Marshall Wace’s Editas Medicine EDIT Stock Holding History

Marshall Wace’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$519K	Buy	+210,308	New	+$445K	﹤0.01%	2432
2025 Q3	–	Sell	-142,008	Closed	-$312K	–	2993
2025 Q2	$312K	Sell	142,008 -100,368	-41%	-$164K	﹤0.01%	2314
2025 Q1	$281K	Buy	+242,376	New	+$357K	﹤0.01%	2294
2024 Q4	–	Sell	-63,759	Closed	-$217K	–	2684
2024 Q3	$217K	Sell	63,759 -385,394	-86%	-$1.68M	﹤0.01%	2272
2024 Q2	$2.1M	Sell	449,153 -342,167	-43%	-$1.93M	﹤0.01%	1350
2024 Q1	$5.87M	Sell	791,320 -319,882	-29%	-$2.66M	0.01%	941
2023 Q4	$11.3M	Sell	1,111,202 -1,083,604	-49%	-$9.51M	0.02%	654
2023 Q3	$17.1M	Sell	2,194,806 -643,511	-23%	-$5.52M	0.03%	488
2023 Q2	$23.4M	Buy	+2,838,317	New	+$24.7M	0.05%	426
2023 Q1	–	Sell	-23,867	Closed	-$212K	–	2773
2022 Q4	$212K	Buy	+23,867	New	+$262K	﹤0.01%	2687
2022 Q2	–	Sell	-17,725	Closed	-$337K	–	3519
2022 Q1	$337K	Sell	17,725 -368,902	-95%	-$6.86M	﹤0.01%	2935
2021 Q4	$10.3M	Buy	+386,627	New	+$13.3M	0.02%	844
2019 Q1	–	Sell	-17,905	Closed	-$408K	–	1800
2018 Q4	$408K	Buy	+17,905	New	+$487K	﹤0.01%	1167

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace's EDIT Position: Q1 2026 in Review

Marshall Wace opened a new position in Editas Medicine (EDIT) in Q1 2026: 210,308 shares worth $519K. The stake represents ﹤0.01% of the portfolio and ranks #2432 among its holdings. This is a return to the name: Marshall Wace previously reported a position in EDIT as recently as Q2 2025.

Marshall Wace first reported a position in EDIT in Q4 2018 and has held it in 13 quarters since. The position peaked at $23.4M in Q2 2023. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Marshall Wace held 210,308 shares of Editas Medicine worth $519K as of Q1 2026.
Editas Medicine was a new Marshall Wace position in Q1 2026.
Editas Medicine made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2432 holding.
Marshall Wace first reported a position in Editas Medicine in Q4 2018 and has held it in 13 quarters since.
Marshall Wace's Editas Medicine position peaked at $23.4M in Q2 2023.
207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.